
Verdiperstat Fails to Improve ALS Disease Progression, HEALEY-ALS Results Show
Official results from the verdiperstat (Biohaven) arm of the HEALEY-ALS Platform trial (NCT04297683), a double-blind, perpetual platform design study, were recently published in JAMA Network. Overall, treatment with the investigational agent at 600 mg …